Agios Pharmaceuticals (NASDAQ:AGIO) Stock: Insider Sarah Gheuens Sells 7,866 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Sarah Gheuens sold 7,866 shares of the company’s stock in a transaction on Monday, October 26th. The shares were sold at an average price of $37.69, for a total value of $296,469.54. Following the transaction, the insider directly owned 54,645 shares in the company, valued at $2,059,570.05. The trade was a 12.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sarah Gheuens also recently made the following trade(s):

• On Thursday, October 22nd, Sarah Gheuens sold 500 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $37.52, for a total value of $18,760.00.
• On Wednesday, October 21st, Sarah Gheuens sold 1,489 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $37.53, for a total value of $55,882.17.
• On Tuesday, August 4th, Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $30.48, for a total value of $914,400.00.

Agios Pharmaceuticals Price Performance

Shares of AGIO opened at $37.23 on Friday. The company has a market capitalization of $2.22 billion, a price-to-earnings ratio of -5.31 and a beta of 0.63. Agios Pharmaceuticals, Inc. has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The business’s 50-day moving average is $33.69 and its 200-day moving average is $31.69.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. The company had revenue of $44.75 million for the quarter, compared to analyst estimates of $26.39 million. Equities research analysts expect that Agios Pharmaceuticals, Inc. will post -5.83 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in Agios Pharmaceuticals in the third quarter worth $101,000. VIRGINIA RETIREMENT SYSTEMS ET Al increased its position in Agios Pharmaceuticals by 4.0% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 28,861 shares of the biopharmaceutical company’s stock worth $960,000 after buying an additional 1,100 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Agios Pharmaceuticals by 15.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,893 shares of the biopharmaceutical company’s stock valued at $363,000 after buying an additional 1,428 shares in the last quarter. Inspire Investing LLC raised its holdings in Agios Pharmaceuticals by 4.7% during the third quarter. Inspire Investing LLC now owns 19,130 shares of the biopharmaceutical company’s stock valued at $636,000 after buying an additional 861 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in Agios Pharmaceuticals by 1,714.6% during the third quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock valued at $62,723,000 after buying an additional 1,782,457 shares in the last quarter.

Analyst Ratings Changes

AGIO has been the subject of a number of research reports. Truist Financial decreased their target price on shares of Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating for the company in a research note on Wednesday, October 7th. HC Wainwright began coverage on shares of Agios Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $55.00 price target on the stock. Royal Bank Of Canada increased their price objective on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a report on Tuesday, July 7th. Bank of America lifted their price objective on Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Finally, JPMorgan Chase & Co. boosted their target price on Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Agios Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.50.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.